Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research note released on Friday,Benzinga reports. They currently have a $22.00 target price on the stock.

A number of other brokerages have also recently weighed in on YMAB. Wedbush restated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. BMO Capital Markets lowered their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.14.

Y-mAbs Therapeutics Stock Down 3.9 %

Shares of NASDAQ YMAB opened at $11.14 on Friday. Y-mAbs Therapeutics has a twelve month low of $5.04 and a twelve month high of $20.90. The firm has a market cap of $498.96 million, a PE ratio of -20.63 and a beta of 0.68. The business has a fifty day simple moving average of $13.98 and a two-hundred day simple moving average of $13.05.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the previous year, the business earned ($0.18) earnings per share. On average, research analysts expect that Y-mAbs Therapeutics will post -0.64 earnings per share for the current year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now directly owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Joris Wilms sold 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. This represents a 14.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,338,100 in the last ninety days. Company insiders own 22.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its stake in shares of Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after acquiring an additional 47,846 shares in the last quarter. Barclays PLC raised its holdings in Y-mAbs Therapeutics by 433.4% in the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after purchasing an additional 56,244 shares during the period. State Street Corp boosted its position in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Caligan Partners LP increased its position in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after buying an additional 613,175 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth approximately $44,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.